Information  X 
Enter a valid email address

IQ-AI Limited (IQAI)

  Print      Mail a friend

Friday 10 July, 2020

IQ-AI Limited

New Development Aims to Detect Tumor Infiltration

RNS Number : 5973S
IQ-AI Limited
10 July 2020
 

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration

 

On the 19 th June,  t he IQ -AI Board announced it was exploring a number of new initiative s and are looking at the wider  application of IB technology and products. "IB CAD" is the first of such new developments.

 

IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC   (IB) has commenced the development of a cancer imaging technology, "IB CAD",that will detect cancer cells before they are visible on standard imaging.  

 

By combiningmulti-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms,IB CAD willprovide a structured way in which infiltrating tumor cells can be identified. In effect,IB CADwill have the potential to detect   andidentify sites of infiltrating tumor growth not visible with current imaging methods. IB CADhas the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement forcancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.

 

Most brain tumor patients will undergo surgical resection with post-surgical therapy. T he survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason,N eurosurgeons will usually remove neighboring   tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, r esidual tumor   remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

 

Approximately 50% of all cancer patients receive some sort of radiotherapyper the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023 . This growth, however, is restricted by the inability to visualise areas of tumor 1 . The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

 

Trevor Brown, IQ-AI CEO  commented "This is a major new development. IB CADwill signify a paradigm shift in brain tumor management and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects areunder preparation by the IB team and I will be communicating in detail on these over coming weeks"

 

 

Ref 1:  Allied Market Research  

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

ABOUT Imaging Biometrics™ , LLC

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visuali s ation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visuali s ation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com .

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RESKKCBQABKDKOK

a d v e r t i s e m e n t